SHINE believes that fusion will ultimately become humanity’s primary source of energy. However, reaching this point requires time, investment, and practical solutions. That is why SHINE has adopted a scalable approach that addresses critical challenges at every stage, designing and operating innovative fusion systems for short-term applications such as medical isotope production and advanced material testing. These steps are laying the solid foundation for a future powered by fusion energy.

What truly differentiates SHINE from other fusion companies is that it has already commercialized fusion today and begun scaling its technology. Across its four-phase roadmap, SHINE continues to perfect the essential competencies for commercially viable fusion, deliver valuable products, create sustainable shareholder value, and invest in long-term growth.

As Nukleon, we are proud to serve as the authorized distributor of the n.c.a.(non-carrier added) Lutetium-177 product-ILUMIRA, being a promising active pharmaceutical ingredient in the treatment of various types of cancer, including neuroendocrine tumors and prostate cancer, of SHINE in the Turkish market.

For more information, you can visit the link www.shinefusion.com.